EPO vs Myostatin Inhibitor
A side-by-side research comparison of EPO and Myostatin Inhibitor across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | EPO | Myostatin Inhibitor |
|---|---|---|
| Full name | Erythropoietin (EPO) | Myostatin Inhibitor Peptides (Anti-GDF-8) |
| Category | Muscle Growth | Muscle Growth |
| Status | FDA-approved drug (prescription) | Research compound |
| Mechanism | Binds erythropoietin receptors on bone marrow progenitor cells, stimulating proliferation and maturation of red blood cells. More red cells raise oxygen-carrying capacity, but also thicken the blood. | Propeptide mimics bind mature myostatin; peptide aptamers block ActRIIB; small antagonists compete for receptor. All prevent myostatin-mediated suppression of muscle growth. |
| Molecular weight | ~34 kDa (glycosylated) | 2,000-15,000 Da (varies) |
| Half-life | ~4-13 hours (varies by formulation) | 4-48 hours (design-dependent) |
| Bioavailability | Subcutaneous or intravenous injection | Variable (SubQ) |
| Typical dose | Prescription-only, condition-specific | 50-500 mcg |
| Frequency | Per medical protocol | 3-7x per week |
| Route | Subcutaneous or IV injection | Subcutaneous |
EPO reported benefits
- Increases red blood cell production
- Treats anemia (medical use)
- Raises oxygen-carrying capacity
Myostatin Inhibitor reported benefits
- Muscle growth promotion
- Strength increase
- Myostatin blockade
- Muscle wasting treatment potential
- Metabolic improvement
Related comparisons
Research and educational reference only. Not medical advice.